AlzeCure Pharma AB (publ) announced that an abstract on its preclinical project TrkA-NAM against osteoarthritis pain and other severe pain conditions has been accepted for presentation at the IASP 2024 World Congress on Pain in Amsterdam on August 5-9. The abstract, titled Pharmacological Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA, will be presented at the global pain conference IASP 2024 World Congress On Pain by Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure. The other authors include Gunnar Nordvall, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-F Hernandez, Johan Sandin and Marta Segerdahl. The presentation includes new preclinical results describing the properties of the recently selected drug candidate for TrkA-NAM, ACD137.

The data show that the substance is a potent and selective negative modulator of NGF/TrkA signaling in cell-based assays. New data in several different preclinical pain models also show clear and significant analgesic effects of ACD137. Interest in TrkA-NAM has also increased further after Asahi Kasei recently started its phase 2b study with AK-1830 against knee osteoarthritis, which validates AlzeCure's project, where developed molecules that are even more potent and selective than AK-1830.